Companies in #MASH
Found 2 companies operating in this sector.
MetaVia is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing therapies for liver-related cardiometabolic disease. Formerly NeuroBo Pharmaceuticals, it renamed itself in November 2024 and now centres on two assets licensed from Korean manufacturer Dong-A ST: DA-1726, a once-weekly oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor agonist, and DA-1241 (vanoglipel), an oral GPR119 agonist being developed for MASH. DA-1726 reported a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at Day 109 in the Phase 1 Part 3B interim analysis presented in November 2026, and the company is planning a 48-week Phase 2 study in metabolic dysfunction and alcohol-associated liver disease. The company held roughly $12.6 million of cash at June 30, 2026, with Dong-A ST as its largest shareholder at 26.8%.
Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its lead candidate, VK2735, is a dual agonist of the GLP-1 and GIP receptors being developed in subcutaneous and oral formulations for obesity and related conditions, with the Phase 3 VANQUISH 1 and 2 subcutaneous trials fully enrolled and an oral Phase 3 programme initiating. In September 2026 the company reported positive topline results from a maintenance-dosing study of subcutaneous VK2735, showing 17.7% mean weight loss after a 21-week induction phase with efficacy maintained under less frequent dosing regimens. The pipeline also includes VK2809, an oral thyroid hormone receptor beta agonist for metabolic dysfunction-associated steatohepatitis, and VK0214 for X-linked adrenoleukodystrophy.